{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:05:21Z","timestamp":1794413121388,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The A1762T\/G1764A double mutant in the basal core promoter (BCP) region of the hepatitis B virus\u00a0(HBV) is associated with severe hepatic lesions while the G1899A mutation with the double mutant is associated with a significant reduction in the risk of severe fibrosis. This study aims to measure a number of markers in the serum of patients with\u00a0chronic HBV\u00a0infection and to assess relationships between these markers and BCP\/precore mutants with consideration of the stage of fibrosis. The serum levels of resistin, TGF-\u03b21, MMP-1, TIMP-1, collagen IA1 and PDGF-BB, which are markers that are known to be involved in the process of hepatic fibrosis, were assayed. The serum levels of PDGF-BB and TIMP-1, and the mutation profile were independently associated with advanced fibrosis. A higher level of TIMP-1 was associated with advanced fibrosis regardless of the mutation status, and a higher level of PDGF-BB was associated with nonsevere fibrosis in patients infected with viruses harboring the A1762T\/G1764A or A1762T\/G1764A\/G1899A mutations. Our results suggest an impact of the A1762T\/G1764A mutant on the biological pathway related to TGF-\u03b21 and PDGF-BB. In vitro studies are needed to understand the impact of these mutants on the serum secretion of markers involved in fibrosis severity.<\/jats:p>","DOI":"10.1038\/s41598-022-14285-9","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:03:18Z","timestamp":1655481798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of hepatic fibrosis markers in the serum of chronic hepatitis B patients according to basal core promoter\/precore mutants"],"prefix":"10.1038","volume":"12","author":[{"given":"Caroline","family":"Lefeuvre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Le Guillou-Guillemette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Lunel-Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Pivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ducancelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"14285_CR1","unstructured":"World Health Organization. Hepatitis B. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b (2021)."},{"key":"14285_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12929-015-0199-y","volume":"22","author":"J-F Wu","year":"2015","unstructured":"Wu, J.-F. & Chang, M.-H. Natural history of chronic hepatitis B virus infection from infancy to adult life: The mechanism of inflammation triggering and long-term impacts. J. Biomed. Sci. 22, 92 (2015).","journal-title":"J. Biomed. Sci."},{"key":"14285_CR3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","volume":"61","author":"M-L Chang","year":"2014","unstructured":"Chang, M.-L. & Liaw, Y.-F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J. Hepatol. 61, 1407\u20131417 (2014).","journal-title":"J. Hepatol."},{"key":"14285_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"Y-F Liaw","year":"2009","unstructured":"Liaw, Y.-F. & Chu, C.-M. Hepatitis B virus infection. Lancet 373, 582\u2013592 (2009).","journal-title":"Lancet"},{"key":"14285_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1365-2893.2002.00304.x","volume":"9","author":"ML Funk","year":"2002","unstructured":"Funk, M. L., Rosenberg, D. M. & Lok, A. S. F. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 9, 52\u201361 (2002).","journal-title":"J. Viral Hepat."},{"key":"14285_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042891","volume":"7","author":"B Kitab","year":"2012","unstructured":"Kitab, B. et al. Variability in the precore and core promoter regions of HBV strains in Morocco: Characterization and impact on liver disease progression. PLoS ONE 7, e42891 (2012).","journal-title":"PLoS ONE"},{"key":"14285_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jhep.2006.03.007","volume":"45","author":"J-P Zarski","year":"2006","unstructured":"Zarski, J.-P. et al. Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. J. Hepatol. 45, 355\u2013360 (2006).","journal-title":"J. Hepatol."},{"key":"14285_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","volume":"2","author":"WF Carman","year":"1989","unstructured":"Carman, W. F. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2, 588\u2013591 (1989).","journal-title":"Lancet"},{"key":"14285_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/hep.21249","volume":"44","author":"A Ozasa","year":"2006","unstructured":"Ozasa, A. et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatolology. 44, 326\u2013334 (2006).","journal-title":"Hepatolology."},{"key":"14285_CR10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1478-3231.2007.01585.x","volume":"27","author":"MJ Tong","year":"2007","unstructured":"Tong, M. J., Blatt, L. M., Kao, J.-H., Cheng, J. T. & Corey, W. G. Basal core promoter T1762\/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: A comparison with chronic carriers. Liver Int. 27, 1356\u20131363 (2007).","journal-title":"Liver Int."},{"key":"14285_CR11","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1128\/jvi.70.9.5845-5851.1996","volume":"70","author":"VE Buckwold","year":"1996","unstructured":"Buckwold, V. E., Xu, Z., Chen, M., Yen, T. S. & Ou, J. H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845\u20135851 (1996).","journal-title":"J. Virol."},{"key":"14285_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/jnci\/djp180","volume":"101","author":"S Liu","year":"2009","unstructured":"Liu, S. et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysis. J. Natl. Cancer Inst. 101, 1066\u20131082 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"14285_CR13","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1128\/JCM.43.12.6000-6006.2005","volume":"43","author":"C-H Chen","year":"2005","unstructured":"Chen, C.-H. et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol. 43, 6000\u20136006 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"14285_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/carcin\/bgq195","volume":"32","author":"X Bai","year":"2011","unstructured":"Bai, X. et al. Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis 32, 63\u201368 (2011).","journal-title":"Carcinogenesis"},{"key":"14285_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038394","volume":"7","author":"Y Liao","year":"2012","unstructured":"Liao, Y. et al. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: Evidence from an updated meta-analysis. PLoS ONE 7, e38394 (2012).","journal-title":"PLoS ONE"},{"key":"14285_CR16","first-page":"497","volume":"27","author":"Y Yang","year":"2015","unstructured":"Yang, Y., Sun, J.-W., Zhao, L.-G., Bray, F. & Xiang, Y.-B. Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: A meta-analysis of prospective studies. Chin. J. Cancer Res. 27, 497\u2013508 (2015).","journal-title":"Chin. J. Cancer Res."},{"key":"14285_CR17","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jgh.13338","volume":"31","author":"A Ducancelle","year":"2016","unstructured":"Ducancelle, A. et al. Different precore\/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. J. Gastroenterol. Hepatol. 31, 1750\u20131756 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"14285_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri, A., Gattolliat, C.-H. & Asselah, T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 155, 629\u2013647 (2018).","journal-title":"Gastroenterology"},{"key":"14285_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655\u20131669 (2008).","journal-title":"Gastroenterology"},{"key":"14285_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/vim.2014.0142","volume":"28","author":"D Ming","year":"2015","unstructured":"Ming, D. et al. Elevated TGF-\u03b21\/IL-31 pathway is associated with the disease severity of hepatitis B virus-related liver cirrhosis. Viral Immunol. 28, 209\u2013216 (2015).","journal-title":"Viral Immunol."},{"key":"14285_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12876-016-0558-5","volume":"17","author":"Z Meng","year":"2017","unstructured":"Meng, Z. et al. High serum resistin associates with intrahepatic inflammation and necrosis: An index of disease severity for patients with chronic HBV infection. BMC Gastroenterol. 17, 6 (2017).","journal-title":"BMC Gastroenterol."},{"key":"14285_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1046\/j.1440-1746.1999.01821.x","volume":"14","author":"Y Murawaki","year":"1999","unstructured":"Murawaki, Y., Ikuta, Y., Idobe, Y. & Kawasaki, H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol. 14, 138\u2013145 (1999).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"Suppl 2","key":"14285_CR23","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0399-8320(10)70028-2","volume":"34","author":"P Bedossa","year":"2010","unstructured":"Bedossa, P. Liver fibrosis in hepatitis B: A dynamic process. Gastroenterol. Clin. Biol. 34(Suppl 2), S103-108 (2010).","journal-title":"Gastroenterol. Clin. Biol."},{"key":"14285_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4137\/BMI.S10009","volume":"7","author":"T Liu","year":"2012","unstructured":"Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J. & Genovese, F. Molecular serum markers of liver fibrosis. Biomark. Insights 7, 105\u2013117 (2012).","journal-title":"Biomark. Insights"},{"key":"14285_CR25","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00261-017-1211-7","volume":"42","author":"JM Horowitz","year":"2017","unstructured":"Horowitz, J. M. et al. Evaluation of hepatic fibrosis: A review from the society of abdominal radiology disease focus panel. Abdom. Radiol. N. Y. 42, 2037\u20132053 (2017).","journal-title":"Abdom. Radiol. N. Y."},{"key":"14285_CR26","doi-asserted-by":"publisher","first-page":"18131","DOI":"10.3748\/wjg.v20.i48.18131","volume":"20","author":"M Soresi","year":"2014","unstructured":"Soresi, M., Giannitrapani, L., Cervello, M., Licata, A. & Montalto, G. Non invasive tools for the diagnosis of liver cirrhosis. World J. Gastroenterol. 20, 18131\u201318150 (2014).","journal-title":"World J. Gastroenterol."},{"key":"14285_CR27","first-page":"2357","volume":"59","author":"X-C Diang","year":"2012","unstructured":"Diang, X.-C. et al. Association between serum platelet-derived growth factor BB and degree of liver damage, fibrosis and hepatitis B e antigen (HBeAg) status in CHB patients. Hepatogastroenterology. 59, 2357\u20132360 (2012).","journal-title":"Hepatogastroenterology."},{"key":"14285_CR28","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3748\/wjg.v9.i11.2490","volume":"9","author":"B-B Zhang","year":"2003","unstructured":"Zhang, B.-B. et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J. Gastroenterol. 9, 2490\u20132496 (2003).","journal-title":"World J. Gastroenterol."},{"key":"14285_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1751-2980.2012.00629.x","volume":"13","author":"CL Zhu","year":"2012","unstructured":"Zhu, C. L., Li, W. T., Li, Y. & Gao, R. T. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J. Dig. Dis. 13, 558\u2013563 (2012).","journal-title":"J. Dig. Dis."},{"key":"14285_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1572-0241.2004.04055.x","volume":"99","author":"V Leroy","year":"2004","unstructured":"Leroy, V. et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: Comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol. 99, 271\u2013279 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"14285_CR31","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2353\/ajpath.2006.060081","volume":"169","author":"C Bertolani","year":"2006","unstructured":"Bertolani, C. et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol. 169, 2042\u20132053 (2006).","journal-title":"Am. J. Pathol."},{"key":"14285_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI115821","volume":"90","author":"WA Border","year":"1992","unstructured":"Border, W. A. & Ruoslahti, E. Transforming growth factor-beta in disease: The dark side of tissue repair. J. Clin. Invest. 90, 1\u20137 (1992).","journal-title":"J. Clin. Invest."},{"key":"14285_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3892\/ijmm.2012.1148","volume":"30","author":"Q Bai","year":"2012","unstructured":"Bai, Q. et al. HBV promotes the proliferation of hepatic stellate cells via the PDGF-B\/PDGFR-\u03b2 signaling pathway in vitro. Int. J. Mol. Med. 30, 1443\u20131450 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"14285_CR34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(89)92760-8","volume":"1","author":"R Ross","year":"1989","unstructured":"Ross, R. Platelet-derived growth factor. Lancet 1, 1179\u20131182 (1989).","journal-title":"Lancet"},{"key":"14285_CR35","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.3748\/wjg.v11.i21.3260","volume":"11","author":"N Akpolat","year":"2005","unstructured":"Akpolat, N., Yahsi, S., Godekmerdan, A., Demirbag, K. & Yalniz, M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J. Gastroenterol. 11, 3260\u20133263 (2005).","journal-title":"World J. Gastroenterol."},{"key":"14285_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8278(99)80001-4","volume":"30","author":"H Tsushima","year":"1999","unstructured":"Tsushima, H. et al. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: Association with regression of hepatic fibrosis. J. Hepatol. 30, 1\u20137 (1999).","journal-title":"J. Hepatol."},{"key":"14285_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1046\/j.1365-2893.2001.00314.x","volume":"8","author":"S Kanzler","year":"2001","unstructured":"Kanzler, S. et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J. Viral Hepat. 8, 430\u2013437 (2001).","journal-title":"J. Viral Hepat."},{"key":"14285_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1006\/cyto.1999.0660","volume":"12","author":"R Flisiak","year":"2000","unstructured":"Flisiak, R., Pytel-Krolczuk, B. & Prokopowicz, D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 12, 677\u2013681 (2000).","journal-title":"Cytokine"},{"key":"14285_CR39","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1515\/cclm-2018-0357","volume":"57","author":"SM Haghgoo","year":"2019","unstructured":"Haghgoo, S. M., Sharafi, H. & Alavian, S. M. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: A systematic review. Clin. Chem. Lab. Med. 57, 577\u2013610 (2019).","journal-title":"Clin. Chem. Lab. Med."},{"key":"14285_CR40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijid.2016.06.004","volume":"49","author":"J Zhou","year":"2016","unstructured":"Zhou, J. et al. Serum platelet-derived growth factor BB levels: A potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B. Int. J. Infect. Dis. 49, 94\u201399 (2016).","journal-title":"Int. J. Infect. Dis."},{"key":"14285_CR41","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.1007\/s11033-012-1509-z","volume":"39","author":"NE El-Bassiouni","year":"2012","unstructured":"El-Bassiouni, N. E. et al. Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma. Mol. Biol. Rep. 39, 6843\u20136850 (2012).","journal-title":"Mol. Biol. Rep."},{"key":"14285_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067833","volume":"8","author":"ED Kantor","year":"2013","unstructured":"Kantor, E. D., Lampe, J. W., Kratz, M. & White, E. Lifestyle factors and inflammation: Associations by body mass index. PLoS ONE 8, e67833 (2013).","journal-title":"PLoS ONE"},{"key":"14285_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.nut.2011.06.007","volume":"28","author":"M Siervo","year":"2012","unstructured":"Siervo, M. et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition 28, 262\u2013266 (2012).","journal-title":"Nutrition"},{"key":"14285_CR44","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1053\/j.gastro.2014.08.038","volume":"147","author":"S Yoshida","year":"2014","unstructured":"Yoshida, S. et al. Extrahepatic platelet-derived growth factor-\u03b2, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 147, 1378\u20131392 (2014).","journal-title":"Gastroenterology"},{"key":"14285_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2006.04359.x","volume":"22","author":"M Kajihara","year":"2007","unstructured":"Kajihara, M. et al. Evaluation of platelet kinetics in patients with liver cirrhosis: Similarity to idiopathic thrombocytopenic purpura. J. Gastroenterol. Hepatol. 22, 112\u2013118 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"14285_CR46","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1136\/gutjnl-2015-309300","volume":"66","author":"J Bayliss","year":"2017","unstructured":"Bayliss, J. et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 66, 2013\u20132023 (2017).","journal-title":"Gut"},{"key":"14285_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1046\/j.1365-2893.2002.00343.x","volume":"9","author":"MG Neuman","year":"2002","unstructured":"Neuman, M. G. et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J. Viral Hepat. 9, 134\u2013140 (2002).","journal-title":"J. Viral Hepat."},{"key":"14285_CR48","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","volume":"17","author":"PA Revill","year":"2020","unstructured":"Revill, P. A. et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat. Rev. Gastroenterol. Hepatol. 17, 618\u2013634 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"14285_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology 24, 289\u2013293 (1996).","journal-title":"Hepatology"},{"key":"14285_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.20535","volume":"41","author":"M-C Rousselet","year":"2005","unstructured":"Rousselet, M.-C. et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41, 257\u2013264 (2005).","journal-title":"Hepatology"},{"key":"14285_CR51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","volume":"39","author":"J-P Villeneuve","year":"2003","unstructured":"Villeneuve, J.-P. et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39, 1085\u20131089 (2003).","journal-title":"J. Hepatol."},{"key":"14285_CR52","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/hep.510290418","volume":"29","author":"M Friedt","year":"1999","unstructured":"Friedt, M. et al. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatol. Baltim. Md 29, 1252\u20131258 (1999).","journal-title":"Hepatol. Baltim. Md"},{"key":"14285_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/3001968","volume":"1","author":"F Wilcoxon","year":"1945","unstructured":"Wilcoxon, F. Individual comparisons by ranking methods. Biom. Bull. 1, 80\u201383 (1945).","journal-title":"Biom. Bull."},{"key":"14285_CR54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","volume":"47","author":"WH Kruskal","year":"1952","unstructured":"Kruskal, W. H. & Wallis, W. A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47, 583\u2013621 (1952).","journal-title":"J. Am. Stat. Assoc."},{"key":"14285_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/00401706.1960.10489894","volume":"2","author":"RGD Steel","year":"1960","unstructured":"Steel, R. G. D. A rank sum test for comparing all pairs of treatments. Technometrics 2, 197\u2013207 (1960).","journal-title":"Technometrics"},{"key":"14285_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","volume":"25","author":"S L\u00ea","year":"2008","unstructured":"L\u00ea, S., Josse, J. & Husson, F. FactoMineR: An R package for multivariate analysis. J. Stat. Softw. 25, 1 (2008).","journal-title":"J. Stat. Softw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14285-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:37:50Z","timestamp":1669354670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14285"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14285-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10261"}}